Holen Sie sich die Stockscreener-App
21.11
9.83%
1.89
Handel nachbörslich:
20.69
-0.42
-1.99%
Schlusskurs vom Vortag:
$19.22
Offen:
$19.52
24-Stunden-Volumen:
197.56K
Relative Volume:
1.06
Marktkapitalisierung:
$301.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.85%
1M Leistung:
-1.49%
6M Leistung:
+12.47%
1J Leistung:
-38.24%
1-Tages-Spanne:
$19.52
$21.59
1-Wochen-Bereich:
$18.94
$22.25
52-Wochen-Spanne:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
21.11 | 290.23M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene Inc. Could See a Relief Rally From Support2025 Performance Recap & Free AI Powered Buy and Sell Recommendations - 선데이타임즈
Has Neurogene Inc. formed a bullish divergenceGlobal Markets & Stock Timing and Entry Methods - Newser
How to read the order book for Neurogene Inc. [Quarterly Growth Report]Daily Entry Point Alerts - Newser
Neurogene Inc. stock trend outlook and recovery pathBear Market Safe Zone Technical Analysis - Newser
What risks could impact Neurogene Inc. stock performanceMarket Timing Strategy with Technical Filters - Newser
Neurogene Inc. shares fall 5.31% intraday despite positive corporate updates and financial results. - AInvest
Institutional scanner results for Neurogene Inc.Chart-Based Entry Confirmation for Beginners - Newser
Price momentum metrics for Neurogene Inc. explainedInvestment Roadmap for High Potential Stocks - Newser
How to read the order book for Neurogene Inc.Long-Term Stock Growth Forecast Insights - Newser
Neurogene Inc. Reports Increased Losses Amid R&D Focus - TipRanks
How Neurogene Inc. stock performs during market volatilityWeekly High Return Portfolio - classian.co.kr
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome - TipRanks
Neurogene: Q2 Earnings Snapshot - San Francisco Chronicle
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Yahoo Finance
Neurogene (NGNE) Files 8-K: Q2 2025 Results Press Release - Stock Titan
Can trapped investors hope for a rebound in Neurogene Inc.Low-Risk Reversal Pattern Analysis Tracker - Newser
How to monitor Neurogene Inc. with trend dashboardsFree Low Risk High Return Opportunities - Newser
Using data models to predict Neurogene Inc. stock movementPrice Action Based Buy Zone Forecast - Newser
Is Neurogene Inc. reversing from oversold territorySummary of Reliable Long-Term Trade Models - Newser
Will Neurogene Inc. bounce back from current supportAI Model Forecasting Reversal and Breakout Zones - Newser
What makes Neurogene Inc. stock price move sharplyDaily Exit and Entry Price Prediction - Newser
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Bank of New York Mellon Corp Acquires 1,844 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Visual analytics tools that track Neurogene Inc. performanceFree Risk Controlled Short Term Trade Plans - Newser
Neurogene Inc. Moves Into Bullish Territory Based on MACDFast Gaining Stock Screener Reports Released - metal.it
What is the risk reward ratio of investing in Neurogene Inc. stockFree Bull & Bear Market Updates - Jammu Links News
Is Neurogene Inc. stock overvalued or undervaluedUnlock powerful stock screening tools today - Jammu Links News
What drives Neurogene Inc. stock priceUnlock powerful market trend analysis - Jammu Links News
How strong is Neurogene Inc. company’s balance sheetTrack high-yield stocks before they peak - Jammu Links News
How volatile is Neurogene Inc. stock compared to the marketUnlock daily trading alerts for profits - Jammu Links News
What are Neurogene Inc. company’s key revenue driversBuild your wealth with consistent stock growth - Jammu Links News
What analysts say about Neurogene Inc. stockAchieve rapid portfolio growth with expert help - Jammu Links News
Is it the right time to buy Neurogene Inc. stockFree Stock Market Trend Analysis - Jammu Links News
What are analysts’ price targets for Neurogene Inc. in the next 12 monthsMaximize portfolio growth with strategic plans - Jammu Links News
What markets is DRTSW expanding into Is Neurogene Inc. stock a good long term investment optionAchieve breakthrough profits with smart strategies - Jammu Links News
What are the latest earnings results for Neurogene Inc.Identify undervalued stocks poised to rally - Jammu Links News
Neurogene Inc. stock retracement – recovery analysisSmart Trend Analysis With Buy Point Cues - Newser
Can machine learning forecast Neurogene Inc. recoveryFree Fast Gaining Stock Screener Report - Newser
Chart based analysis of Neurogene Inc. trendsIntraday Signal Forecast for Fast Traders - Newser
Neurogene (NGNE) to Release Earnings on Friday - Defense World
Order flow analysis tools used on Neurogene Inc.Short-Term Price Breakout Signal Analysis - Newser
Ranking Neurogene Inc. among high performing stocks via toolsConsistent Profit Signals with AI Models - Newser
What institutional investors are buying Neurogene Inc. stockDaily Trading Review That Work - Jammu Links News
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):